VIR Q1 2023 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M-94.9% YoY

Gross Profit

-$97M-153.4% margin

Operating Income

-$143M-227.7% margin

Net Income

-$141M-223.8% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

+27.4%

Cash Flow

Operating Cash Flow

-$126M

Free Cash Flow

-$133M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$695M

Stockholders' Equity

$2.0B

Cash & Equivalents

$825M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$1.2B	-94.9%
Gross Profit	-$97M	$1.1B	-109.2%
Operating Income	-$143M	$1.0B	-114.1%
Net Income	-$141M	$519M	-127.2%

Revenue Segments

Collaboration Revenue

$47M100%

Contract Revenue

$138,0000%